The U.S. FDA will accept for review Eli Lilly's supplemental Biologics License Application (sBLA) for EBGLYSS (lebrikizumab) for hand and foot atopic dermatitis by November 29, 2026.
Posted 2026-09-30 — 60 days before the deadline, stated before the outcome.
The claim
The U.S. FDA will accept for review Eli Lilly's supplemental Biologics License Application (sBLA) for EBGLYSS (lebrikizumab) for hand and foot atopic dermatitis by November 29, 2026.
Reasoning trace
- Signpost: FDA accepts Lilly's sBLA for EBGLYSS in hand and foot atopic dermatitis
- Potential label expansion for EBGLYSS, broadening Lilly's immunology franchise
Evidence so far
0 confirming · 0 denying signals · 2 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 1 time since mint (last on 2026-09-30) — 78% at mint → 84% today.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.